Cyclerion.com

Cyclerion.com has Server used 151.101.130.159 IP Address with Hostname in United States. Below listing website ranking, Similar Webs, Backlinks. This domain was first 2018-08-29 (2 years, 256 days) and hosted in Manchester United States, server ping response time 19 ms

DNS & Emails Contact

This tool is used to extract the DNS and Emails from this domain uses to contact the customer.

Fetching Emails ...

Extract All Emails from Domain

Top Keywords Suggestions

Keywords suggestion tool used Cyclerion keyword to suggest some keywords related from this domain. If you want more, you can press button Load more »

1 Cyclerion.com
2 Cyclerion ir
3 Cyclerion gmbh
4 Cyclerion logo
5 Cyclerion news
6 Cyclerion layoff
7 Cyclerion stock
8 Cyclerion thera
9 Cyclerion ticker

Hosting Provider

Website: Cyclerion.com
Hostname: 151.101.130.159
Country:
Region: NH
City: Manchester
Postal Code: 03101
Latitude: 42.988498687744
Longitude: -71.465202331543
Area Code: 603
Email AbuseNo Emails Found

Find Other Domains on Any IP/ Domain


New! Domain Extensions Updated .com .org .de .net .uk   » more ...

Domains Actived Recently

   » Nursing.com (7 seconds ago)

   » Mireene.com (6 seconds ago)

   » Desertoracle.com (0 seconds ago)

   » Midwestmarinesupply.com (15 seconds ago)

   » Misgood.com (0 seconds ago)

   » Moochie-poochie.com (5 seconds ago)

   » Ccprc.com (9 seconds ago)

   » Reims-tourism.com (10 seconds ago)

   » Florestourtransport.com (6 seconds ago)

Results For Websites Listing

Found 45 Websites with content related to this domain, It is result after search with search engine

Cyclerion Therapeutics, Inc. (CYCN) Stock Price, News

Finance.yahoo.com   DA: 17 PA: 12 MOZ Rank: 29

About Cyclerion Therapeutics Cyclerion Therapeutics is a clinical-stage biopharmaceutical company on a mission to develop treatments that restore cognitive function. Cyclerion’ is advancing novel,

Stock Alert: Cyclerion Therapeutics Jumps 13% As CEO

Nasdaq.com   DA: 14 PA: 50 MOZ Rank: 65

  • (RTTNews) - Shares of Cyclerion Therapeutics, Inc
  • (CYCN) are rising more than 13% Friday morning at $2.83.As per SEC filing by Cyclerion on May 6, …

CYCN Stock Price Cyclerion Therapeutics Inc. Stock Quote

Marketwatch.com   DA: 19 PA: 21 MOZ Rank: 42

  • is a clinical-stage biopharmaceutical company, which engages in the discovery, development, and commercialization of treatments for serious

Cyclerion Therapeutics, Inc. (CYCN) Stock Price Today

Seekingalpha.com   DA: 16 PA: 12 MOZ Rank: 31

Cyclerion Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovering, development, and commercialization of medicines for …

Cyclerion Therapeutics, Inc. (CYCN) Latest Stock News

Finance.yahoo.com   DA: 17 PA: 17 MOZ Rank: 38

  • Shares of clinical-stage biotech Cyclerion Therapeutics (NASDAQ: CYCN) are down by an eye-popping 48% as of noon EDT Wednesday
  • The small-cap biotech's stock is crashing in response to a negative

Here Is Why Cyclerion Therapeutics Inc. (CYCN) Stock

Investchronicle.com   DA: 19 PA: 50 MOZ Rank: 74

  • had a pretty Dodgy run when it comes to the market performance
  • The 1-year high price for the company’s stock is recorded $6.90 on 02/04/21, with the lowest value was $2.08 for the same time period, recorded on 05/03/21
  • (CYCN) full year performance was -37.75%

Cyclerion Is A Speculative Biotech With A Few Catalysts

Seekingalpha.com   DA: 16 PA: 50 MOZ Rank: 72

  • Cyclerion Therapeutics (CYCN) holds potential as a highly speculative biotech
  • There are a few near-term catalysts that investors may need to keep an eye on that are rapidly approaching

Why Cyclerion Therapeutics Is Crashing Today The Motley Fool

Fool.com   DA: 12 PA: 50 MOZ Rank: 69

Cyclerion is thus planning to assess the drug across a broad range of central nervous system disorders, including mitochondrial encephalomyopathy, lactic …

Cyclerion Therapeutics, Inc. Company Profile Cambridge

Dnb.com   DA: 11 PA: 50 MOZ Rank: 69

  • is located in Cambridge, MA, United States and is part of the Pharmaceutical Manufacturing Industry. Cyclerion Therapeutics, Inc
  • has 143 total employees across all of its locations and generates $2.30 million in sales (USD)
  • There are 2 companies in the Cyclerion Therapeutics, Inc

If You’re Not Bullish On Cyclerion Therapeutics, Inc

Stocksregister.com   DA: 18 PA: 50 MOZ Rank: 77

  • (NASDAQ:CYCN) price closed higher on Friday, May 07, jumping 10.84% above its previous close
  • Get the hottest stocks to trade every day before the market opens 100% free
  • A look at the daily price movement shows that …

Cyclerion Therapeutics, Inc.

Zacks.com   DA: 13 PA: 21 MOZ Rank: 44

  • is a clinical-stage biopharmaceutical company harnessing the power of sGC pharmacology to discover, develop and commercialize breakthrough treatments for serious and

CYCN Cyclerion Therapeutics Inc — Stock Price And

Stocktwits.com   DA: 14 PA: 12 MOZ Rank: 37

  • Cyclerion Therapeutics Inc NASDAQ Updated May 7, 2021 11:59 PM

Cyclerion Therapeutics Appoints Errol De Souza, Ph.D., To

Globenewswire.com   DA: 21 PA: 50 MOZ Rank: 83

Cyclerion Therapeutics is a clinical-stage biopharmaceutical company on a mission to develop treatments that restore cognitive function. Cyclerion’s lead molecule is CY6463, a novel,

Cyclerion Therapeutics Appoints Errol De Souza, Ph.D., To

Biospace.com   DA: 16 PA: 50 MOZ Rank: 79

Cyclerion Therapeutics is a clinical-stage biopharmaceutical company on a mission to develop treatments that restore cognitive function. Cyclerion’s lead molecule is CY6463, a novel, first-in-class, CNS-penetrant, sGC stimulator that modulates a key node in …

Cyclerion Therapeutics Stock Analysis

Macroaxis.com   DA: 17 PA: 43 MOZ Rank: 74

  • Cyclerion Therapeutics price slide over the last few months could raise concerns from institutional investors as the firm it trading at a share price of 2.61 on 452,318 in volume
  • The company directors and management were not very successful in positioning the firm resources to exploit market volatility in March.However, diversifying your holdings with Cyclerion Therapeutics or similar stocks

Cyclerion Therapeutics To Participate In The B. Riley

Globenewswire.com   DA: 21 PA: 50 MOZ Rank: 86

Cyclerion Therapeutics is a clinical-stage biopharmaceutical company on a mission to develop treatments that restore cognitive function. Cyclerion’s lead molecule is CY6463, a novel,

Statement Of Changes In Beneficial Ownership (4)

Ih.advfn.com   DA: 12 PA: 50 MOZ Rank: 78

  • 1 day ago · C/O CYCLERION THERAPEUTICS, INC., 245 FIRST STREET, 18TH FLOOR: 3
  • Date of Earliest Transaction (MM/DD/YYYY) 5/6/2021 (Street) CAMBRIDGE, MA 02142 (City) (State) (Zip) 4
  • If Amendment, Date Original Filed (MM/DD/YYYY) 6
  • Individual or Joint/Group Filing (Check Applicable Line) _X _ Form filed by One Reporting Person

Cyclerion Therapeutics, Inc. (NASDAQ:CYCN) Climbs 43% In

Marketingsentinel.com   DA: 21 PA: 50 MOZ Rank: 88

  • Cyclerion Therapeutics, Inc.’s shares saw a change of -8.49% in year-to-date performance and have moved 28.44% in past 5-day
  • (NASDAQ:CYCN) showed a performance of -2.77% in past 30-days
  • Number of shares sold short was 717.86 Million shares which calculate 0.99 days to cover the short interests.

Riding The Trend Or Protecting Profits Cyclerion

Newsheater.com   DA: 14 PA: 50 MOZ Rank: 82

  • (NASDAQ:CYCN) went down by -17.05% from its latest closing price compared to the recent 1-year high of $8.96
  • The company’s stock price has collected 28.40% of gains in the last five trading sessions
  • Press Release reported on 04/26/21 that Cyclerion Therapeutics Appoints Errol De Souza, Ph.D., to Board of Directors
  • Get the hottest stocks to trade …

Cyclerion Therapeutics Announces Departure Of Chief

Nasdaq.com   DA: 14 PA: 50 MOZ Rank: 83

  • About Cyclerion Therapeutics Cyclerion Therapeutics is a clinical-stage biopharmaceutical company on a mission to develop treatments that restore cognitive function

Why Cyclerion Therapeutics Is Crashing Today

Msn.com   DA: 11 PA: 50 MOZ Rank: 81

Cyclerion is thus planning to assess the drug across a broad range of central nervous system disorders, including mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes.

Why Cyclerion, Sol-Gel, Aldeyra, DermTech And Bionano

Benzinga.com   DA: 16 PA: 50 MOZ Rank: 87

Cyclerion Slips On Study Delay: Cyclerion, a clinical-stage biopharma developing treatments for restoring cognitive functions, provided a clinical …

Cyclerion Therapeutics Inc. [CYCN] Fell -16.34% So Far

Dbtnews.com   DA: 11 PA: 50 MOZ Rank: 83

  • [NASDAQ: CYCN] stock went on a downward path that fall over -17.95% on Tuesday, amounting to a one-week price decrease of less than -1.92%
  • The company report on April 27, 2021 that Cyclerion Therapeutics Hosted …

Stock Alert: Cyclerion Therapeutics Jumps 13% As CEO

Rttnews.com   DA: 15 PA: 50 MOZ Rank: 88

  • Shares of Cyclerion Therapeutics, Inc
  • are rising more than 13% Friday morning at $2.83.As per SEC filing by Cyclerion on May 6, 2021, its CEO Peter Hecht has increased his stake by adding 698,001 shares of the company, at an average price of $2.43 per share for about $1.7 million.

Cyclerion Therapeutics, Inc. (NASDAQ:CYCN) Stock Forecast

Marketingsentinel.com   DA: 21 PA: 50 MOZ Rank: 95

  • (CYCN) projections and forecasts
  • Looking at the company’s year-over-year earnings, the past five years showed a negative earnings growth rate of 0%
  • earnings are expected to increase by 43% in 2021, but the outlook is negative 0% per year for the next five years.

Cyclerion Fails Sickle Cell Test, Prompting Pivot To CNS

Fiercebiotech.com   DA: 21 PA: 50 MOZ Rank: 96

  • Cyclerion Therapeutics has stopped development of olinciguat in sickle cell disease after getting a look at data from a phase 2 trial
  • The setback prompted Cyclerion to switch its …

How Volatile Is Cyclerion Therapeutics Stock Today

Macroaxis.com   DA: 17 PA: 39 MOZ Rank: 82

  • Cyclerion Therapeutics Stock volatility depicts how high the prices fluctuate around the mean (or its average) price
  • In other words, it is a statistical measure of the distribution of Cyclerion daily returns, and it is calculated using variance and standard deviation.

Current Report Filing (8-k)

Ih.advfn.com   DA: 12 PA: 50 MOZ Rank: 89

  • CYCN Cyclerion Therapeutics Inc Current Report Filing (8-k) Cyclerion Therapeutics, Inc
  • (the “Company”) has announced that Errol De Souza was appointed to the Company’s board of directors (the "Board") on April 21, 2021
  • De Souza’s appointment was made immediately after the Board increased the size of the Board from eight to nine members.

Cyclerion Therapeutics Trading Near Cash; Offers A

Forbes.com   DA: 14 PA: 50 MOZ Rank: 92

Cyclerion Therapeutics is a clinical-stage biopharmaceutical company harnessing the power of sGC pharmacology to discover, develop, and commercialize breakthrough treatments for …

Cyclerion Therapeutics

Crunchbase.com   DA: 18 PA: 50 MOZ Rank: 97

  • Cyclerion Therapeutics has raised a total of $199M in funding over 2 rounds
  • Their latest funding was raised on Jul 31, 2020 from a Post-IPO Equity round
  • Cyclerion Therapeutics is registered under the ticker NASDAQ:CYCN
  • Cyclerion Therapeutics is funded by 3 investors
  • Slate Path Capital and Pappas Capital are the most recent investors.

Cyclerion Therapeutics Appoints Errol De Souza, Ph.D., To

Markets.businessinsider.com   DA: 27 PA: 50 MOZ Rank: 20

About Cyclerion Therapeutics Cyclerion Therapeutics is a clinical-stage biopharmaceutical company on a mission to develop treatments that restore cognitive function.

Cyclerion Therapeutics Reports Third Quarter 2020

Markets.businessinsider.com   DA: 27 PA: 50 MOZ Rank: 19

Cyclerion Therapeutics is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing innovative medicines for people with serious diseases of …

Ironwood Pharmaceuticals, Inc.

Investor.ironwoodpharma.com   DA: 27 PA: 50 MOZ Rank: 18

Cyclerion, the Planned R&D Spin-off of Ironwood Pharmaceuticals, Secures Commitments of $175 Million in Private Offering – Proceeds to advance Cyclerion’s soluble guanylate cyclase (sGC) programs targeting breakthrough treatments for serious and orphan diseases – – Spin-off expected to be completed in early April 2019 –

Is Cyclerion Therapeutics Inc (CYCN) A Stock To Watch

Investorsobserver.com   DA: 25 PA: 50 MOZ Rank: 17

  • Cyclerion Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing the power of soluble guanylate cyclase (sGC) pharmacology to discover, develop and commercialize breakthrough treatments for serious and orphan diseases
  • Its focus is on enabling the full therapeutic potential of next-generation sGC stimulators.

Ironwood Pharmaceuticals Announces Chief Executive

Businesswire.com   DA: 20 PA: 50 MOZ Rank: 16

  • Peter Hecht will become CEO and a director of Cyclerion Therapeutics, Inc
  • (Cyclerion), the soluble guanylate cyclase (sGC) biotechnology business focused on …

Phase 2a Study Of IW-6463 In Adults Diagnosed With MELAS

Clinicaltrials.gov   DA: 18 PA: 21 MOZ Rank: 74

Cyclerion Therapeutics: ClinicalTrials.gov Identifier: NCT04475549 Other Study ID Numbers: C6463-201 CY6463 ( Other Identifier: Cyclerion Therapeutics ) First Posted: July 17, 2020 Key Record Dates: Last Update Posted: February 10, 2021 Last Verified: February 2021

A Study Of The Effects Of CY6463 In Participants With

Clinicaltrials.gov   DA: 18 PA: 21 MOZ Rank: 75

Cyclerion Therapeutics: ClinicalTrials.gov Identifier: NCT04798989 Other Study ID Numbers: C6463-202 : First Posted: March 16, 2021 Key Record Dates: Last Update Posted: March 16, 2021 Last Verified: March 2021 Individual Participant Data …

Cyclerion Therapeutics Reports Full Year 2020 Financial

Biospace.com   DA: 16 PA: 50 MOZ Rank: 13

  • Cyclerion Therapeutics is a clinical-stage biopharmaceutical company on a mission to develop treatments that restore cognitive function
  • Cyclerion’s lead program is CY6463, a novel, first-in-class, CNS-penetrant, sGC stimulator that modulates a key node in …

Cambridge Biotech Cyclerion Hires Ex-Shire Exec

Bizjournals.com   DA: 19 PA: 50 MOZ Rank: 12

Cyclerion has hired the former chief medical officer at Shire plc for a new, overarching role focused on bridging R&D, external partnerships and other business facets.

Cyclerion Therapeutics To Host Pipeline Update Webinar

Benzinga.com   DA: 16 PA: 50 MOZ Rank: 11

  • Cyclerion Therapeutics is a clinical-stage biopharmaceutical company on a mission to develop treatments that restore cognitive function
  • Cyclerion's lead molecule is CY6463, a …

Recently Analyzed Sites

Nursing.com (8 seconds ago)

Mireene.com (7 seconds ago)

Desertoracle.com (1 seconds ago)

Midwestmarinesupply.com (16 seconds ago)

Misgood.com (1 seconds ago)

Moochie-poochie.com (6 seconds ago)

Ccprc.com (10 seconds ago)

Reims-tourism.com (11 seconds ago)

Florestourtransport.com (7 seconds ago)

Kizi10.org (6 seconds ago)

Nurse.org (8 seconds ago)

Medicalhair4u.com (4 seconds ago)

Corporatetasting.com (0 seconds ago)

Anadagitim.net (9 seconds ago)

Amvata.com (24 seconds ago)

Cyclerion.com (1 seconds ago)

Allied-clinical.com (19 seconds ago)